Search research articles
Contact Us
Filters
Showing results (71-80 of 142) with videos related to
Page
of 15
Sort By:
Blood
|
February 2, 2006
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
Jane N Winter, Edie A Weller, Sandra J Horning, et al.
Blood Advances
|
July 24, 2025
Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and Efficacy
Oluwatobi Odetola, Shuo Ma, Jane N Winter, et al.
Leukemia & Lymphoma
|
June 21, 2023
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma
Danielle S Wallace, Chris Rowland, Brian T Hill, et al.
Blood Advances
|
September 9, 2022
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
Pamela B Allen, Xinyan Lu, Qing Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study
Anjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
Andrew M Evens, Fangxin Hong, Thomas M Habermann, et al.
British Journal of Haematology
|
March 4, 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
Michael Wang, Leslie L Popplewell, Robert H Collins, et al.
Blood
|
May 3, 2014
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
Mitul D Gandhi, Andrew M Evens, Timothy S Fenske, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Timothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 21, 2010
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era
Andrew M Evens, Kevin A David, Irene Helenowski, et al.
Page
of 15
Search research articles
Search
Showing results (71-80 of 142) with videos related to
Sort By:
Page
of 15
Blood
|
February 2, 2006
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
Jane N Winter, Edie A Weller, Sandra J Horning, et al.
Blood Advances
|
July 24, 2025
Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and Efficacy
Oluwatobi Odetola, Shuo Ma, Jane N Winter, et al.
Leukemia & Lymphoma
|
June 21, 2023
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma
Danielle S Wallace, Chris Rowland, Brian T Hill, et al.
Blood Advances
|
September 9, 2022
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
Pamela B Allen, Xinyan Lu, Qing Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study
Anjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
Andrew M Evens, Fangxin Hong, Thomas M Habermann, et al.
British Journal of Haematology
|
March 4, 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
Michael Wang, Leslie L Popplewell, Robert H Collins, et al.
Blood
|
May 3, 2014
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
Mitul D Gandhi, Andrew M Evens, Timothy S Fenske, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Timothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 21, 2010
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era
Andrew M Evens, Kevin A David, Irene Helenowski, et al.
Page
of 15